Key result
Antihypertensive therapy in guideline-eligible adults is linked to ~23% lower all-cause mortality.
Why the study?
The long-term population-level changes following the August 2025 AHA/ACC updated hypertension guidelines remained uncertain.
Does antihypertensive therapy reduce all-cause and cardiovascular mortality in hypertensive adults eligible under the 2025 AHA/ACC guidelines?
Cohort
Yes
Does antihypertensive therapy reduce all-cause and cardiovascular mortality in hypertensive adults eligible under the 2025 AHA/ACC guidelines?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I wouldn't say the direction of the findings was surprising, but the magnitude certainly was. What stood out most was the size of the treatment gap — over 40% of people who were clearly eligible under the new guideline were not receiving treatment. That really highlights that the issue is not just defining who should be treated, but ensuring those recommendations are implemented in real-world practice.”
“I was also struck by the scale of the potential benefit. When we modeled full implementation, treating all eligible individuals could prevent over 200,000 deaths over 10 years, which shows how relatively modest individual risk reductions can translate into very large population-level gains.”
“The 2025 guideline emphasizes a personalized approach to managing high blood pressure by considering blood pressure levels plus 10-year and 30-year overall cardiovascular disease risk. The American Heart Association's PREVENT risk equations help to identify individuals who could benefit from treatment before a major cardiac event. Controlling blood pressure is crucial for long-term health.”
Applying the 2025 AHA/ACC hypertension guidelines to treat eligible US adults could prevent over 200,000 all-cause and 160,000 cardiovascular deaths over a decade.
BACKGROUND: In August 2025, the American Heart Association and American College of Cardiology released updated hypertension guidelines. Under the new guidelines, therapy is advised at blood pressure ≥130/80 mm Hg in adults with diabetes, chronic kidney disease, or a Predicting Risk of Cardiovascular Disease Events-estimated 10-year cardiovascular disease risk ≥7.5%. The long-term population-level changes following these guidelines remains uncertain. METHODS: We analyzed NHANES (National Health and Nutrition Examination Survey) 2009 to 2018 data linked to mortality through 2019. Hypertensive adults without baseline cardiovascular disease were included. Treatment eligibility was defined using guideline criteria. Cox models estimated associations between antihypertensive therapy and all-cause and cardiovascular mortality. Simulation analyses projected lives saved under full and partial treatment uptake. RESULTS: The weighted cohort represented 81.0 million US adults with hypertension. Of these, 22.8 million (28%) were guideline eligible for therapy; 13.1 million (57%) were treated, and 9.7 million (43%) remained untreated. Antihypertensive therapy was associated with a 23% reduction in all-cause mortality (hazard ratio [HR], 0.77 [95% CI, 0.63-0.94]) and 50% reduction in cardiovascular mortality (HR, 0.50 [95% CI, 0.36-0.68]). At 10 years, universal treatment of eligible but untreated adults was projected to prevent ~200 900 all-cause and ~ 162 600 cardiovascular deaths. Benefits were greatest in adults with diabetes. CONCLUSIONS: In this nationally representative cohort, nearly 1 in 3 US adults with hypertension were newly eligible for therapy under the guideline, yet >2 in 5 remained untreated. Extending treatment to all eligible adults could prevent >200 000 all-cause and 160 000 cardiovascular deaths over the next decade.
No takes yet. Share an insight, caveat, or question.
Al-Jarshawi et al. (2026) conducted a cohort in Hypertension. Antihypertensive therapy vs. Untreated was evaluated on All-cause mortality (HR 0.77, 95% CI 0.63-0.94). Antihypertensive therapy in guideline-eligible adults was associated with reduced all-cause mortality and cardiovascular mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: